DNA damage is one of the foundational causes of cancer. But researchers have now found that deliberately causing DNA damage – by delivering additional treatments like radiotherapy – could improve the effectiveness of immunotherapy for some people with kidney cancer.

Scientists have found that non-coding ‘junk’ DNA, far from being harmless and inert, could potentially contribute to the development of cancer.

The ICR strongly welcomes new findings that the targeted drug olaparib improves survival in women with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes.